Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.43 |
| ▸ | XDH | P47989 | 2/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6052114 | 0.88 | RORC (0.41) | ALDH1A1HPGDS1PR1RORC | |
| SCHEMBL9635254 | 0.87 | ALDH1A1 (0.48) | ALDH1A1HPGDXDHACE2RORC | |
| SCHEMBL404481 | 0.84 | KDM4E (0.43) | ALDH1A1HPGDS1PR1XDHRORC | |
| SCHEMBL3586801 | 0.83 | ALDH1A1 (0.56) | ALDH1A1HPGD | |
| SCHEMBL6541867 | 0.82 | ALDH1A1 (0.48) | ALDH1A1HPGDXDHACE2 | |
| SCHEMBL4719671 | 0.81 | CA12 (0.47) | ALDH1A1HPGDRORC | |
| SCHEMBL3977562 | 0.80 | ALDH1A1 (0.49) | ALDH1A1HPGDACE2 | |
| SCHEMBL22664370 | 0.80 | RORC (0.61) | S1PR1XDHRORC | |
| SCHEMBL30339997 | 0.79 | ALDH1A1 (0.56) | ALDH1A1HPGD | |
| SCHEMBL28343734 | 0.79 | ALDH1A1 (0.47) | ALDH1A1HPGDXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563785-A1 | COMPOUNDS AS AGONISTS OF S1P1 RECEPTORS | Glaxo Group Limited (GB) | 2013-03-06 | — | — | EP | disclosed |
| US-8389508-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-8389508-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| EP-2206710-B1 | Indole derivatives as S1P1 receptor agonists | GLAXO GROUP LTD (GB) | 2012-07-04 | — | — | EP | disclosed |
| EP-2206710-B1 | Indole derivatives as S1P1 receptor agonists | GLAXO GROUP LTD (GB) | 2012-07-04 | — | — | EP | disclosed |
| EP-2443112-A1 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-04-25 | — | — | EP | disclosed |
| US-20120094979-A1 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-04-19 | — | — | US | disclosed |
| EP-1452528-B1 | XANTHINE OXIDASE INHIBITORS | NIPPON CHEMIPHAR CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008074821-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074821-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| US-20070265283-A1 | Xanthine Oxidase Inhibitor | NIPPON CHEMIPHAR CO., LTD. | 2007-11-15 | — | — | US | disclosed |
| US-7253154-B2 | Substituted thiazolopyrimidines as xanthine oxidase inhibitors | NIPPON CHEMIPHAR CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| US-7015218-B1 | Amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-21 | — | — | US | disclosed |
| US-20050090472-A1 | Xanthine oxidase inhibitors | NIPPON CHEMIPHAR CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1176140-B1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| EP-1452528-A1 | XANTHINE OXIDASE INHIBITORS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2004-09-01 | — | — | EP | disclosed |
| EP-1176140-A1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2002-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094979-A1 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | S1PR1, S1PR5, S1PR2 | ALDH1A1 1412/4885HPGD 1171/4885S1PR1 1/4885 |
| US-20050090472-A1 | Xanthine oxidase inhibitors | XDH, CBR1, NOX1 | ALDH1A1 706/4885HPGD 621/4885S1PR1 3581/4885 |
| US-20070265283-A1 | Xanthine Oxidase Inhibitor | XDH, CBR1, NOX1 | ALDH1A1 671/4885HPGD 644/4885S1PR1 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.